Key themes and takeaways from the IFC’s Emerging Markets conference

Last month, thought leaders from private healthcare systems across the globe gathered in Cape Town, South Africa, to network, share their findings, and consider how emerging markets can become more resilient. HBI was there, and these are our key themes and takeaways.

Shareholders unconvinced by “future Fresenius”

Michael Sen, CEO of multinational healthcare conglomerate Fresenius, finally set out his long-awaited plan for a “Future Fresenius” at the group’s end of year results this week. But is it a radical shake up, or PR puff? HBI investigates why shareholders appear unconvinced.

Fresenius to deconsolidate FMC

Michael Sen, the new CEO of multinational health care conglomerate Fresenius, is making preparations to deconsolidate struggling dialysis subsidiary Fresenius Medical Care (FMC). The plans fall short of full divestment and may not be radical enough to appease investors.

FMC CEO leaves after just two months in post

Global renal disease specialist Fresenius Medical Care has parted ways with its new CEO just months after announcing her appointment, and scarcely two months after she took up her post. HBI looks at the surprisingly quick turnaround and tries to work out what happened.

Is Bridgepoint looking to sell Diaverum in Q4?

Swedish pan-European dialysis group Diaverum could be up for sale in Q4. Reports suggest PE owner Bridgepoint has reportedly appointed American investment bank Citi to review strategic options for a sale.

Fresenius: “We’re not selling”

Germany-based healthcare conglomerate Fresenius tells HBI it isn't currently looking to carve off parts of its business for sale, and despite mixed H1 results it sees plenty of opportunities for growth.

HBI 2022: Balance of power in MENA is shifting

There is a risk, when looking at healthcare markets in MENA, of lumping all the countries together as one - but each market has very specific requirements, and very specific characteristics. A panel at HBI 2022 chaired by Hamid Yunis, partner at global law firm McDermott Will & Emery, investigated challenges and opportunities in the region - and how rapidly the markets are changing and why overseas players now need to work harder to impress.

Interview, Kirsty Bashforth, Chief business officer, Diaverum

Chronic Kidney Disease is a continuing to rise, further impacted by COVID and the wider economic burden. We discuss how digitalisation, improving health literacy and a more holistic approach could make a difference to the outlook in this sector with Kirsty Bashforth, chief business officer, Diaverum, ahead of her How to Build a Brand workshop at HBI 2022. 

Find Us